Aardvark Therapeutics, INC 10-Q quarterly reports

Aardvark Therapeutics reports significant clinical trial setbacks for ARD-101, including an FDA clinical hold and trial terminations, leading to increased operating expenses and net losses.

Aardvark Therapeutics announced a voluntary pause in its clinical trials for ARD-101 and ARD-201 due to reversible cardiac observations in a healthy volunteer study, impacting development timelines and future guidance.

Aardvark Therapeutics reports increased R&D spending and net losses in Q3 2025, driven by clinical trial advancements for ARD-101 and ARD-201, while maintaining a strong cash position into 2027.

Aardvark Therapeutics, a clinical-stage biopharmaceutical company, reported significantly increased net losses and cash burn for Q2 2025, alongside a delay in topline data for its lead PWS drug candidate, ARD-101.

Aardvark Therapeutics announces its financial results for the first quarter of 2025, emphasizing the advancement of its Phase 3 clinical trial for ARD-101 in Prader-Willi Syndrome.